• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有变构结合小分子激动剂的人黄体生成素 G 蛋白偶联受体突变体的表达和信号转导的挽救。

Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist.

机构信息

Centre for Integrative Physiology, School of Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom.

出版信息

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7172-6. doi: 10.1073/pnas.1015723108. Epub 2011 Apr 11.

DOI:10.1073/pnas.1015723108
PMID:21482767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3084114/
Abstract

Naturally occurring mutations of G protein-coupled receptors (GPCRs) causing misfolding and failure to traffic to the cell surface can result in disease states. Some small-molecule orthosteric ligands can rescue such misfolded receptors, presumably by facilitating their correct folding and shuttling to the plasma membrane. Here we show that a cell-permeant, allosterically binding small-molecule agonist (Org 42599) rescues the folding and cell surface expression, and therefore target cell signaling, of mutant human luteinizing hormone (LH) receptors (A593P and S616Y) that cause Leydig cell hypoplasia in man. Both mutant receptors were retained in the cytoplasm whereas WT receptor localized at the cell membrane, and binding of LH to cells expressing the mutant receptors was markedly lower than to those expressing the WT receptor. Incubation with Org 42599 increased mutant receptor expression, cell surface localization, and the proportion of mutant receptor in the mature glycosylated form. Importantly, although LH stimulated little (S616Y) or no (A593P) activation of cells expressing mutant receptors, incubation of cells with Org 42599 facilitated rescue of expression and stimulation by the native ligand, LH. Although Org 42599 could activate these receptors, it could not displace (125)I-labeled human LH binding to the WT receptor, indicating that it acts in an allosteric manner. Here we demonstrate a small-molecule GPCR allosteric agonist that functionally rescues intracellularly retained mutant LH receptors by facilitating their cell surface expression. This approach may have application for treatment of infertile patients bearing such mutations and, more broadly, for other misfolded GPCR mutants resulting in human pathologic processes.

摘要

天然存在的 G 蛋白偶联受体 (GPCR) 突变会导致错误折叠和无法运输到细胞表面,从而导致疾病状态。一些小分子正构配体可以挽救这种错误折叠的受体,推测是通过促进其正确折叠和转运到质膜。在这里,我们表明一种细胞渗透性、变构结合的小分子激动剂 (Org 42599) 可以挽救突变型人促黄体生成激素 (LH) 受体 (A593P 和 S616Y) 的折叠和细胞表面表达,从而挽救其靶细胞信号转导,这些受体在人体内导致 Leydig 细胞发育不全。两种突变受体都滞留在细胞质中,而 WT 受体定位于细胞膜,并且与表达突变受体的细胞结合的 LH 明显低于与表达 WT 受体的细胞结合的 LH。用 Org 42599 孵育增加了突变受体的表达、细胞表面定位和成熟糖基化形式的突变受体比例。重要的是,尽管 LH 刺激表达突变受体的细胞很少 (S616Y) 或没有 (A593P) 激活,但 Org 42599 的孵育促进了表达和天然配体 LH 的刺激的挽救。尽管 Org 42599 可以激活这些受体,但它不能置换 (125)I 标记的人 LH 与 WT 受体的结合,表明它以变构方式起作用。在这里,我们证明了一种小分子 GPCR 变构激动剂,它通过促进细胞表面表达来功能性地挽救细胞内滞留的突变型 LH 受体。这种方法可能适用于治疗携带此类突变的不孕患者,并且更广泛地适用于导致人类病理过程的其他错误折叠的 GPCR 突变体。

相似文献

1
Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist.具有变构结合小分子激动剂的人黄体生成素 G 蛋白偶联受体突变体的表达和信号转导的挽救。
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7172-6. doi: 10.1073/pnas.1015723108. Epub 2011 Apr 11.
2
Rescue of Function of Mutant Luteinising Hormone Receptors with Deficiencies in Cell Surface Expression, Hormone Binding, and Hormone Signalling.突变促黄体生成素受体的细胞表面表达、激素结合和激素信号缺陷的功能挽救。
Neuroendocrinology. 2021;111(5):451-464. doi: 10.1159/000508000. Epub 2020 Apr 21.
3
Rescue of Cell Surface Expression and Signaling of Mutant Follicle-Stimulating Hormone Receptors.突变卵泡刺激素受体的细胞表面表达和信号转导的挽救。
Endocrinology. 2021 Dec 1;162(12). doi: 10.1210/endocr/bqab134.
4
A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor.一种对人促黄体生成素受体具有信号选择性、纳摩尔效价的变构低分子量激动剂。
Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):503-14. doi: 10.1007/s00210-008-0318-3. Epub 2008 Jun 13.
5
Regulatory processes governing the cell surface expression of LH and FSH receptors.调控促黄体生成素(LH)和促卵泡生成素(FSH)受体细胞表面表达的过程。
Subcell Biochem. 2012;63:113-29. doi: 10.1007/978-94-007-4765-4_7.
6
[3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor.[3H]Org 43553,首个用于人类促黄体生成素受体的低分子量激动性和变构放射性配体。
Mol Pharmacol. 2008 Feb;73(2):518-24. doi: 10.1124/mol.107.039875. Epub 2007 Nov 7.
7
Loss-of-Function Mutations in the Human Luteinizing Hormone Receptor Predominantly Cause Intracellular Retention.人类促黄体生成素受体的功能丧失突变主要导致细胞内滞留。
Endocrinology. 2016 Nov;157(11):4364-4377. doi: 10.1210/en.2016-1104. Epub 2016 Aug 17.
8
Mutant luteinizing hormone receptors in a compound heterozygous patient with complete Leydig cell hypoplasia: abnormal processing causes signaling deficiency.一名患有完全性莱迪希细胞发育不全的复合杂合子患者中的突变促黄体生成素受体:异常加工导致信号缺陷。
J Clin Endocrinol Metab. 2002 Jun;87(6):2506-13. doi: 10.1210/jcem.87.6.8523.
9
A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype.促黄体生成素受体的纯合突变导致部分莱迪希细胞发育不全:受体活性与表型之间的相关性。
Mol Endocrinol. 1998 Jun;12(6):775-84. doi: 10.1210/mend.12.6.0124.
10
Deletions of portions of the extracellular loops of the lutropin/choriogonadotropin receptor decrease the binding affinity for ovine luteinizing hormone, but not human choriogonadotropin, by preventing the formation of mature cell surface receptor.促黄体生成素/绒毛膜促性腺激素受体细胞外环部分的缺失,通过阻止成熟细胞表面受体的形成,降低了对绵羊促黄体生成素的结合亲和力,但对人绒毛膜促性腺激素的结合亲和力没有影响。
J Biol Chem. 1996 Feb 23;271(8):4518-27. doi: 10.1074/jbc.271.8.4518.

引用本文的文献

1
Effect of a Low-Molecular-Weight Allosteric Agonist of the Thyroid-Stimulating Hormone Receptor on Basal and Thyroliberin-Stimulated Activity of Thyroid System in Diabetic Rats.促甲状腺激素受体的低分子量变构激动剂对糖尿病大鼠甲状腺系统基础及促甲状腺素释放激素刺激活性的影响
Int J Mol Sci. 2025 Jan 15;26(2):703. doi: 10.3390/ijms26020703.
2
Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration.泛酸激酶相关神经变性中用于多靶点精准医学的患者来源细胞模型
Pharmaceuticals (Basel). 2023 Sep 26;16(10):1359. doi: 10.3390/ph16101359.
3
Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.别构调节 G 蛋白偶联受体:从分子机制多样性到多个别构结合位点及其配体。
Int J Mol Sci. 2023 Mar 24;24(7):6187. doi: 10.3390/ijms24076187.
4
Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.黑皮质素受体配体:超越黑素细胞刺激素和促肾上腺皮质激素。
Biomolecules. 2022 Oct 1;12(10):1407. doi: 10.3390/biom12101407.
5
Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.针对导致内分泌疾病的错误折叠 GPCR 作为治疗途径的贩运。
Front Endocrinol (Lausanne). 2022 Aug 25;13:934685. doi: 10.3389/fendo.2022.934685. eCollection 2022.
6
Human C1orf27 protein interacts with α-adrenergic receptor and regulates its anterograde transport.人源 C1orf27 蛋白与 α-肾上腺素能受体相互作用并调节其顺行转运。
J Biol Chem. 2022 Jun;298(6):102021. doi: 10.1016/j.jbc.2022.102021. Epub 2022 May 10.
7
Trafficking-defective mutant PROKR2 cycles between endoplasmic reticulum and Golgi to attenuate endoplasmic reticulum stress. trafficking-defective mutant PROKR2 在粗面内质网和高尔基体之间循环,以减轻内质网应激。
Proc Natl Acad Sci U S A. 2022 Feb 22;119(8). doi: 10.1073/pnas.2102248119.
8
Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects.错误折叠的 G 蛋白偶联受体与内分泌疾病。分子机制与治疗前景。
Int J Mol Sci. 2021 Nov 15;22(22):12329. doi: 10.3390/ijms222212329.
9
The Effect of Low-Molecular-Weight Allosteric Agonist of Luteinizing Hormone Receptor on Functional State of the Testes in Aging and Diabetic Rats.促黄体生成素受体低分子量变构激动剂对衰老和糖尿病大鼠睾丸功能状态的影响
Bull Exp Biol Med. 2021 May;171(1):81-86. doi: 10.1007/s10517-021-05177-5. Epub 2021 May 29.
10
Precision Medicine in Rare Diseases.罕见病中的精准医学。
Diseases. 2020 Nov 13;8(4):42. doi: 10.3390/diseases8040042.

本文引用的文献

1
A splice site mutation combined with a novel missense mutation of LHCGR cause male pseudohermaphroditism.一种剪接位点突变与促黄体生成素/绒毛膜促性腺激素受体(LHCGR)的新型错义突变相结合导致男性假两性畸形。
Hum Mutat. 2009 Sep;30(9):E855-65. doi: 10.1002/humu.21072.
2
Drug development and the cellular quality control system.药物研发与细胞质量控制系统。
Trends Pharmacol Sci. 2009 May;30(5):228-33. doi: 10.1016/j.tips.2009.02.002. Epub 2009 Mar 21.
3
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor.通过一种强效、口服活性、低分子量的促黄体生成素受体激动剂(Org 43553)诱导排卵。
Hum Reprod. 2009 Mar;24(3):640-8. doi: 10.1093/humrep/den412. Epub 2008 Dec 16.
4
Asp330 and Tyr331 in the C-terminal cysteine-rich region of the luteinizing hormone receptor are key residues in hormone-induced receptor activation.促黄体生成素受体C末端富含半胱氨酸区域中的Asp330和Tyr331是激素诱导受体激活的关键残基。
J Biol Chem. 2008 Sep 19;283(38):25821-8. doi: 10.1074/jbc.M804395200. Epub 2008 Jul 19.
5
A signaling-selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor.一种对人促黄体生成素受体具有信号选择性、纳摩尔效价的变构低分子量激动剂。
Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):503-14. doi: 10.1007/s00210-008-0318-3. Epub 2008 Jun 13.
6
A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected sister.一种新的促黄体生成素(LH)受体剪接突变,导致先证者出现男性性腺功能减退伴精子生成低于正常水平,以及一名患病姐妹出现月经周期正常但不孕的情况。
Hum Reprod. 2008 Aug;23(8):1917-23. doi: 10.1093/humrep/den180. Epub 2008 May 27.
7
Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines.促性腺激素释放激素(GnRH)受体的质膜表达:拮抗剂对乳腺、前列腺和促性腺激素细胞系的调节作用
J Endocrinol. 2008 Feb;196(2):353-67. doi: 10.1677/JOE-07-0471.
8
In and out of the ER: protein folding, quality control, degradation, and related human diseases.往返于内质网:蛋白质折叠、质量控制、降解及相关人类疾病
Physiol Rev. 2007 Oct;87(4):1377-408. doi: 10.1152/physrev.00050.2006.
9
G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo.G蛋白偶联受体在健康与疾病中的转运:为体内治疗性突变体拯救所汲取的经验教训。
Pharmacol Rev. 2007 Sep;59(3):225-50. doi: 10.1124/pr.59.3.2.
10
Gonadotrophin resistance.促性腺激素抵抗
Best Pract Res Clin Endocrinol Metab. 2006 Dec;20(4):561-76. doi: 10.1016/j.beem.2006.09.003.